Research

Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure

Jan-Peter Braun1, Dominik Jasulaitis2, Maryam Moshirzadeh2, Ulrich R Doepfner1, Marc Kastrup1, Christian von Heymann1, Pascal M Dohmen3, Wolfgang Konertz4 and Claudia Spies5

1Consultant, Department of Anesthesiology and Intensive Care, Campus Charité Mitte, Charité University Hospital, Charité – University Medicine Berlin, Germany
2Medical Doctor, Department of Anesthesiology and Intensive Care, Campus Charité Mitte, Charité University Hospital, Charité – University Medicine Berlin, Germany
3Consultant, Department of Cardiac Surgery, Campus Charité Mitte, Charité University Hospital, Charité – University Medicine Berlin, Germany
4Professor of Cardiovascular Surgery, Director of the Department, Department of Cardiac Surgery, Campus Charité Mitte, Charité University Hospital, Charité – University Medicine Berlin, Germany
5Professor of Anesthesiology, Director of the Department, Department of Anesthesiology and Intensive Care, Campus Charité Mitte, Charité University Hospital, Charité – University Medicine Berlin, Germany

Corresponding author: Jan-Peter Braun, jan.braun@charite.de

Received: 12 Aug 2005 Revisions requested: 21 Oct 2005 Revisions received: 12 Nov 2005 Accepted: 22 Dec 2005 Published: 13 Jan 2006

Critical Care 2006, 10:R17 (doi:10.1186/cc3979)
This article is online at: http://ccforum.com/content/10/1/R17
© 2006 Braun et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Most case series suggest that less than half of the patients receiving a mechanical cardiac assist device as a bridge to recovery due to severe post-cardiotomy heart failure survive to hospital discharge. Levosimendan is the only inotropic substance known to improve medium term survival in patients suffering from severe heart failure.

Methods This retrospective analysis covers our single centre experience. Between July 2000 and December 2004, 41 consecutive patients were treated for this complication. Of these, 38 patients are included in this retrospective analysis as 3 patients died in the operating room. Levosimendan was added to the treatment protocol for the last nine patients.

Results Of 29 patients treated without levosimendan, 20 could be weaned off the device, 9 survived to intensive care unit discharge, 7 left hospital alive and 3 survived 180 days. All 9 patients treated with levosimendan could be weaned, 8 were discharged alive from ICU and hospital, and 7 lived 180 days after surgery ($p < 0.002$ for 180 day survival). Plasma lactate after explantation of the device was significantly lower ($p = 0.002$), as were epinephrine doses. Time spent on renal replacement therapy was significantly shorter ($p = 0.023$).

Conclusion Levosimendan seems to improve medium term survival in patients failing to wean off cardiopulmonary bypass and requiring cardiac assist devices as a bridge to recovery. This retrospective analysis justifies prospective randomised investigations of levosimendan in this group of patients.

Introduction

Failure to wean off cardiopulmonary bypass (CPB) secondary to severe post-cardiotomy cardiac failure is a serious problem in cardiac surgery. Adherence to clearly defined treatment standards has been shown to be advantageous [1-3]. Phosphodiesterase inhibitors and catecholamines are routinely used to treat this complication [4]. In addition to pharmacotherapy, circulation is supported by intraaortic balloon pumping (IABP) and a trial of delayed sternal closure can be indicated [5]. In ongoing severe cardiac failure, mechanical assist devices are used [1-3]. Aims of therapy with these devices are maintenance of adequate perfusion of vital organs and a temporary reduction of cardiac work [6]; centrifugal pumps are commonly used for this purpose. From 49% to 71% of patients are successfully weaned off these devices, and hospital survival is quoted as ranging from 22% to 52% [7-16]. The most commonly encountered complications are bleeding, thrombosis, emboli, renal failure and ongoing severe cardiac failure. Little is known about long term survival of...
patients treated with assist devices for post-cardiotomy heart failure [10].

Our institution, which treats, on average, 1,500 adult patients per year undergoing CPB, introduced levosimendan for treatment of this complication in February 2003. Compared with other inotropes, levosimendan increases myocardial oxygen consumption to a much lesser extent. There seems to be a particularly marked action on stunned myocardium [17]. The intracellular concentration of calcium is not influenced by levosimendan. The second effect of levosimendan is general vasodilation, which leads to an increase of coronary and splanchnic blood flow [18,19]. Levosimendan induced vasodilation is achieved through opening of the ATP-dependent potassium channels of smooth muscle cells, which is one of the most important factors in protecting tissue from ischemia/reperfusion injury [20]. This mechanism is also responsible for the anti-ischemic, cardio-protective properties of levosimendan [21]. Due to active metabolites, the pharmacological effects of levosimendan are present for many days.

We conducted a retrospective review of the outcome of consecutive patients requiring mechanical ventricular assistance with a centrifugal pump for post-cardiotomy heart failure before and after we started using levosimendan for treatment of severe post-cardiotomy heart failure.

**Materials and methods**

We reviewed the charts and data derived from an electronic patient data management system (COPRA™, Leipzig, Germany) of 41 consecutive adult patients undergoing implantation of a centrifugal assist device as a bridge to recovery. Three patients died due to vasoplegia resistant to treatment within the operating room (two conventional treated patients and one patient in the levosimendan group); these patients were excluded from further analysis. From 1 July 2000 to 31 December 2004, 38 patients were included in this analysis and were observed up to 1 June 2005. We determined details of the treatment during the intensive care unit (ICU) stay; if patients were discharged from hospital, we contacted the patients and if necessary their general practitioners by phone to establish survival status.

Our bypass and anesthesia management has been described in our standard operating procedures [22]. In short, for induction of anesthesia we used etomidate, midazolam, fentanyl and pancuronium, and for maintenance of anesthesia fentanyl infusion and isoflurane or sevoflurane were used. CPB was performed using a centrifugal pump (Rotaflow™, Jostra, Hirlingen, Germany) with a pump flow above 2.6 l·min⁻¹·m⁻² and arterial line pressure above 60 mmHg in normothermia. Pump prime consists of balanced electrolyte solution and hydroxyethyl starch. All patients receive 50,000 KIU·kg⁻¹ aprotinin at the

---

**Figure 1**

Treatment protocol of the weaning off from cardiopulmonary bypass in patients with acute or chronic impaired cardiac function. IABP, intra-aortic balloon (contra-)pulsation; ICU, intensive care unit; MAP, mean arterial pressure; TEE, trans-esophageal echocardiography; v O₂ saturation, venous oxygen-saturation.
start of CPB. Cardioplegia is induced and maintained with intermittent antegrade warm potassium enriched blood [23]. During CPB we maintain the hematocrit above 22% by packed red blood cell transfusions.

During termination of CPB all patients described were monitored using transesophageal echocardiography (TEE) using a Sonos 4500 or 5500 System (Hewlett Packard, Andover, Massachusetts, USA) and a pulmonary artery catheter with continuous oxymetry measurement device (Opticath, Abbott, North-Chicago, Illinois, USA). During this period we infused vasoactive substances in every patient according to institutional standards (Figure 1): norepinephrine was applied to maintain mean arterial pressure above 60 mmHg; and in patients with seriously impaired pump function, enoximone 0.3 to 0.5 mg·kg⁻¹ was applied as a slow bolus injection during cardiac reperfusion. If further inotropic support was needed (mixed venous oxygen saturation below 60% and/or cardiac index below 2.4 l·min⁻¹·m⁻²), the patients received epinephrine to a maximum dose of 0.15 µg·kg⁻¹·min⁻¹. If it was impossible to discontinue CPB with this regime we implanted an IABP. During a second attempt to discontinue the pump run we increased the epinephrine dose, if required, up to 0.3 µg·kg⁻¹·min⁻¹. If this attempt was unsuccessful, we proceeded to implantation of a centrifugal pump (Medtronic Biomedicus, Minneapolis, Minnesota, USA). This pump bypassed the ventricle with the worst pump function as judged by TEE and invasive hemodynamic monitoring. If necessary, both ventricles were supported. Goals of hemodynamic therapy were a mixed venous oxygen saturation of 70% or more, and a mean arterial pressure of 70 mmHg. Furthermore, pump flow and filling pressures were adjusted in such a manner that slight opening movements of the aortic valve were visible (during TEE) to avoid intra-cardiac thrombus formation. Epinephrine infusion was guided by the status of the supported ventricle; if possible, doses of less than 0.1 µg·kg⁻¹·min⁻¹ were used. First line inotropic support was with enoximone 3 to 5 µg·kg⁻¹·min⁻¹, reduced to 1 µg·kg⁻¹·min⁻¹ in renal failure. Heart rate was limited to 100 beats per minute using esmolol and metoprolol. In new onset atrial fibrillation, electric cardioversion was attempted. IABPs were triggered by the ECG and 1:1 support was chosen. Blood component therapy was guided by coagulation analysis. Heparin was used to maintain activated partial thromboplastin time (aPTT) around 50 seconds once postoperative blood loss had diminished to less than 50 ml·h⁻¹. The access wound was closed using a plastic membrane or skin sutures depending on the individual situation.

In February 2003, we added levosimendan to our therapy regime as a last pharmacological option. We started applying

**Table 1**

| Characteristic                  | Conventional | Levosimendan | P value |
|---------------------------------|--------------|--------------|---------|
| n                               | 29           | 9            |         |
| Age (years)                     | 68 ± 7*      | 57 ± 8*      | 0.001   |
| Body mass index                 | 27.1 ± 3*    | 26.3 ± 3*    | 0.41    |
| Male:female                     | 19:10        | 8:1          | 0.31    |
| LVEF                            | 34 ± 14*     | 33 ± 17*     | 0.96    |
| Coronary artery disease         | 26           | 7            | 0.55    |
| Arterial hypertension           | 23           | 7            | 0.94    |
| Pulmonary arterial hypertension | 3            | 2            | 0.61    |
| Diabetes mellitus               | 12           | 3            | 0.73    |
| Chronic renal insufficiency     | 10           | 2            | 0.59    |
| Peripheral vascular disease     | 7            | 2            | 0.94    |
| Atrial fibrillation             | 12           | 3            | 0.74    |
| Hyperlipidemia                  | 15           | 4            | 0.42    |
| Nicotine abuse                  | 6            | 4            | 0.13    |
| COPD                            | 5            | 2            | 0.71    |

*Mean ± standard deviation. Mann-Whitney-U test was used to determine p values between the groups. Chi square test was used to compare categorial data. COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction.

**Figure 2**

Epinephrine dosages of the intensive care unit survivors. Boxplots presents medians and 25 and 75 percentiles; limits are the 95 confidence intervals. White boxplots are the values of the maximal epinephrine dosage at the day of surgery, grey boxplots are the mean epinephrine dosages during assist device, striped boxplots are the maximal epinephrine dosage during the first 24 hours after explantation of the assist device and black boxplots are the values of the mean epinephrine dosage during the first 24 hours after explantation of the assist device. Asterisks indicate p < 0.001 between the groups.
the drug in five patients in the operating room during the attempts to wean off CPB and, in four patients, levosimendan therapy was started in the ICU, that is, once the assist had been inserted. We applied an initial bolus dose of 20 $\mu$g·kg$^{-1}$ over ten minutes and then continued therapy with 0.1 to 0.2 $\mu$g·kg$^{-1}$·min$^{-1}$ for a maximum of 48 hours because of the accumulation of active metabolites [24]. Administered in this dosage it has been shown that the pharmacological effects of levosimendan’s active metabolites last for at least one week after the end of application. This dosage was chosen due to the advantageous experiences observed in the LIDO-study [25].

The indication for explantation of the assist system was a successful trial of clamping the device for five to ten minutes without deterioration of the hemodynamic parameters. A mixed venous saturation of 70% or more and a mean arterial pressure of 65 mmHg or more had to be maintained using a dosage of epinephrine of 0.1 $\mu$g·kg$^{-1}$·min$^{-1}$ or less. In this clinical situation every patient received a continuous infusion of enoximone.

Statistical evaluation of our retrospective data was done using SPSS version 12.0 (IAC, Chicago, Illinois, USA). The Mann-Whitney $U$ test was used to make inter group comparisons. To calculate significance in survival differences between groups chi-square-tests were performed. Significance was assessed at $p \leq 0.05$.

### Table 2

| Characteristic | Conventional | Levosimendan | $P$ value |
|---------------|--------------|--------------|-----------|
| CABG          | 17           | 6            | 0.84      |
| AVR           | 2            | 1            | 0.79      |
| MVR           | 4            | 1            | 0.71      |
| CABG + VR     | 6            | 1            | 0.36      |
| Duration of CPB (minutes) | $170 \pm 70^a$ | $176 \pm 101^a$ | 0.65 |
| Duration of AO (minutes) | $69 \pm 60^a$ | $80 \pm 81^a$ | 0.76 |
| LVAD          | 22           | 7            | 0.70      |
| RVAD          | 5            | 1            | 0.95      |
| BiVAD         | 2            | 1            | 0.86      |
| Duration of AD (days) | $3.2 \pm 2^a$ | $3.8 \pm 1.5^a$ | 0.20 |

*Mean ± standard deviation. Mann-Whitney $U$ test was used to calculate $p$-values between the groups (duration data). Chi square test was used to compare categorial data. AO, aortic cross clamping; AVR, aortic valve replacement; BiVAD, biventricular ventricular assist device; CABG, coronary artery bypass grafting; CABG + VR, CABG combination with a valve replacement; CPB, cardiopulmonary bypass; IABP, intra-aortic balloon pump counter-pulsation; LVAD, left ventricular assist device; MVR, mitral valve replacement; RVAD, right ventricular assist device.

### Results

Demographic data and coexisting diagnoses are given in Table 1. Surgical characteristics are given in Table 2. Survival in relation to treatment with levosimendan is shown in Table 3.

There was no relevant difference between the two groups with regard to treatment with enoximone. The average norepinephrine dosages during infusion of levosimendan were not significantly different between patients treated with or without levosimendan: median 0.14 $\mu$g·kg$^{-1}$·min$^{-1}$ (interquartile range 0.18) in the levosimendan group; and median 0.2 (interquartile range 0.28) in the conventional treatment group. On the day of primary surgery, the maximum dose of epinephrine was higher in patients not receiving levosimendan. After explantation, levosimendan patients required less epinephrine (Figure 2). The median of the norepinephrine dosage after explantation was 0.06 $\mu$g·kg$^{-1}$·min$^{-1}$ (interquartile range 0.012) in the levosimendan treated patients versus 0.14 $\mu$g·kg$^{-1}$·min$^{-1}$ (interquartile range 0.4) in the conventional treated patients ($p = 0.03$).
After explantation of the assist device, plasma lactate concentrations were significantly lower in the levosimendan group (Figure 3).

There was no significant difference in duration of mechanical cardiac assistance with either centrifugal pumps (mean 3.4 days, range 1 to 7 days) or IABPs (mean 6.2 days, range 6 to 53 days). Mean time on mechanical ventilation was 6.2 days (range 2 to 44 days), mean ICU stay was 27 days (range 6 to 53 days), and mean hospital stay was 60 days (range 6 to 196) without any significant difference between the groups. The incidence of renal replacement therapy in both groups was 80%, but there was a large difference in duration of renal replacement therapy between the ICU survivors of the two groups (Figure 4).

Discussion

In this retrospective observation, we were able to demonstrate a positive effect of levosimendan on 180-day survival rates in patients with severe post-cardiectomy heart failure. The group of patients treated with levosimendan required less epinephrine in the postoperative period, showed lower plasma lactate concentration after explantation of the assist device, and significantly shorter duration of renal replacement therapy. No difference was found between the groups regarding the incidence of acute renal failure as well as ICU or hospital length of stay.

The survival rates in the conventional treatment group were similar to those reported by other centres; 10 studies observing the therapy with assist device implantation as a bridge to recovery showed that weaning was possible in 49% to 71% and discharge from hospital in 22% to 52% of patients [7-16]. In our study, 69% of the patients in the conventional therapy group were able to be weaned from the assist device and 24% were finally discharged from hospital. In contrast, all of the patients in the levosimendan group were successfully weaned and 89% could be discharged from hospital. We have taken into consideration that the patients in the levosimendan group were of significantly younger age than those in the conventional treatment group (Table 1). The average age of the patients in the levosimendan group was 57 years and ranged between a minimum of 45 years and a maximum of 68 years. This corresponds with an average age of 59 years published in other studies.

Not many data exist on long-term survival rates of patients receiving an assist device secondary to severe post-cardiectomy cardiac shock. Hoy and colleagues [10] have reported 62 cases with implanted centrifugal pumps. In that study, 27 of the observed patients were able to be discharged from hospital, 9 died in the first year after discharge, 10 further survived for less than 5 years, 7 survived for 6 to 10 years and 1 patient survived for more than 10 years after the procedure.

The advantageous effects of levosimendan in patients with acute decompensated cardiac failure have been demonstrated in clinical trials. The multicenter RUSSLAN study [25] investigated levosimendan in three different dosages versus placebo in patients with acutely impaired cardiac function due to myocardial infarction. The higher dosage of levosimendan (bolus 24 µg·kg⁻¹ followed by infusion of 0.4 µg·kg⁻¹·min⁻¹) was associated with increased incidences of hypotension and ischemia compared to patients who received a bolus of 24 µg·kg⁻¹ followed by infusion of 0.2 µg·kg⁻¹·min⁻¹ or patients who received a bolus of 12 µg·kg⁻¹ followed by infusion of 0.2 µg·kg⁻¹·min⁻¹ or patients who received a bolus of 6 µg·kg⁻¹ followed by infusion of 0.1 µg·kg⁻¹·min⁻¹. The total number of levosimendan treated patients showed a significantly reduced 14-day mortality ($p = 0.031$) and the 180-day mortality tended to be lower in the levosimendan groups ($p = 0.023$ between the groups).

### Table 3

| Survival Status | Conventional | Levosimendan | $p$ value |
|-----------------|--------------|--------------|-----------|
| AD survival     | 20           | 9            | $0.082$   |
| ICU survival    | 9            | 8            | $0.005$   |
| Hosp survival   | 7            | 8            | $0.001$   |
| 180-day survival| 3            | 7            | $<0.001$  |

Chi square test was used and $p$ values between the groups were determined according to exact Fischer’s test. 180-day survival, survival of the first 180 days after surgery; AD survival, survival of assist device; Hosp survival, survival of hospital stay; ICU survival, survival of intensive care unit stay.

### Figure 4

Duration of the extracorporal renal replacement. Boxplots present medians and 25 and 75 percentiles; limits are the 95 confidence intervals. The asterisk indicates $p = 0.023$ between the groups.

180-day survival, survival of the first 180 days after surgery; AD survival, survival of assist device; Hosp survival, survival of hospital stay; ICU survival, survival of intensive care unit stay.
since this observation is retrospective. Our data justify future prospective randomised trials of levosimendan in cardiac surgical patients suffering from severe heart failure.

Morelli and co-workers showed that levosimendan improved the left ventricular stroke work index in septic patients with reduced ventricular function compared to patients treated with dobutamine [19]. The authors observed no difference in norepinephrine dosages between the groups. Their patients were treated with optimal fluid loading. In our retrospective analysis, we also found no increase in administered norepinephrine dosages in levosimendan treated patients. In Morelli’s study, levosimendan led to an increase in gastric mucosal blood flow, creatinine clearance, and urinary output. The authors found decreased troponin and lactate concentrations in levosimendan treated patients. In our retrospective observation, the duration of renal replacement therapy was significantly lower in the levosimendan group compared to the conventional therapy group. This could be due to improved renal perfusion.

The significantly lower plasma lactate concentration following device explantation in levosimendan treated patients could possibly be an indicator for improved splanchnic perfusion and for protection of organs from ischemia/reperfusion injury through opening of ATP-dependent potassium channels by levosimendan. Another explanation for this finding could be a reduced administration of epinephrine in the levosimendan group. Epinephrine itself may lead to impaired splanchnic perfusion and metabolic alterations resulting in hyperlactatemia [28].

Conclusion
The 180-day survival rate in patients receiving an assist device due to severe post-cardiotomy cardiac failure was significantly improved by treatment with levosimendan. A significant reduction of the epinephrine dose was possible. The incidence of hyperlactatemia was lower and the duration of renal replacement therapy was shorter.

The results presented here must be interpreted cautiously since this observation is retrospective. Our data justify future prospective randomised trials of levosimendan in cardiac surgical patients suffering from severe heart failure.

Key messages
- Failure to wean off cardiopulmonary bypass (CPB) secondary to severe postcardiotomy cardiac failure is a serious problem in cardiac surgery.
- Adherence to clearly defined treatment standards has been shown to be advantageous.
- In this case series the 180-day survival rate in patients failing to wean off cardiopulmonary bypass and requiring cardiac assist devices as a bridge to recovery was about 10% (3 of 29).
- The 180-day survival rate in 9 patient who were additionally treated with levosimendan was about 78% (7 of 9).
- Our data justify future prospective randomised trials of levosimendan in cardiac surgical patients suffering from severe heart failure.

Competing interests
The authors declare that they have no competing interests.

Acknowledgements
We thank Mrs Gerda Siebert, Institute of Medical Biometry and Statistics of the Humboldt University of Berlin, for the detailed statistical advice.

This investigation was not sponsored by any extramural foundation or financial support.

References
1. Samuels LE, Kaufman MS, Thomas MP, Holmes EC, Brockmann SK, Wechsler AS: Pharmacological criteria for ventricular assist device insertion following post-cardiotomy shock: experiences with Abiomed BVS system. J Card Surg 1999, 14:288-293.
2. Hardly JF, Belisle S: Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass. J Cardiovasc Anesth 1993, 7:33-39.
3. Lewis KP: Early intervention of inotropic support in facilitating weaning from cardiopulmonary bypass: the New England Deaconess Hospital experience. J Cardiovasc Anesth 1993, 7:40-45.
4. Boldt J, Knothe C, Zickmann Ballesteros M, Russ W, Dapper F, Hempelmann P: The role of enoximone in cardiac surgery. Br J Anaesth 1992, 68:49-50.
5. Anderson CA, Fiasouli F, Aklog L, Farivar RS, Byrne JG, Adams DH: Liberal use of delayed sternal closure for post-cardiotomy hemodynamic instability. Ann Thorac Surg 2002, 73:1484-1488.
6. Hill AG, Groom RC, Burton NA, Lefrak EA: Cardiac assist devices. Int Anesthesiol Clin 1996, 34:85-94.
7. Noon GP, Lafuente JA, Irwin S: Acute and temporary ventricular support with BioMedicus centrifugal pump. Ann Thorac Surg 1999, 68:650-654.
8. Korfer R, El Banayosy A, Arusoglu L, Minami K, Breymann T, Seifert D, Kitzner L: Temporary pulsatile ventricular assist devices and biventricular assist devices. Ann Thorac Surg 1999, 68:678-683.
9. Goldstein DJ, Oz MC: Mechanical support for post-cardiotomy cardiogenic shock. Semin Thorac Cardiovasc Surg 2000, 12:220-228.
10. Hoy FB, Mueller DK, Geiss DM, Munns JR, Bond LM, Linett CE, Gomez RC: Bridge to recovery for post-cardiotomy failure: is
there still a role for centrifugal pumps? Ann Thorac Surg 2000, 70:1259-1263.

11. Dekers RJ, FitzGerald DJ, Couper GS: Five-year experience with Abiomed BVS 5000 as a ventricular assist device for cardiac failure. Perfusion 2001, 16:13-18.

12. Magovern JA, Sussman MJ, Goldstein AH, Savage EB, Westby S: Clinical results with the AB-180 left ventricular assist device. Ann Thorac Surg 2001, 71:S121-S124.

13. Samuels LE, Holmes EC, Thomas MP, Entwistle JC 3rd, Morris RJ, Narula J, Wechsler AS: Management of acute cardiac failure with mechanical assist: experience with the ABIOMED BVS 5000. Ann Thorac Surg 2001, 71:S67-S72.

14. Rodrigus IA, Amsel BJ, Conraads V, de Hert S, Moulijn AC: Emergency ventricular assist device: better survival rates in non-post cardiomyopathy-related cardiogenic shock. Acta Chir Belg 2001, 101:226-231.

15. Tisol WB, Mueller DK, Hoy FB, Gomez RC, Clemson BS, Hussein SM: Ventricular assist device use with mechanical heart valves: an outcome series and literature review. Ann Thorac Surg 2001, 72:2051-2054.

16. Curtis JJ, McKenney-Knox CA, Wagner-Mann CC: Post-cardiotomy centrifugal assist: a single surgeon's experience. Artif Organs 2002, 26:994-997.

17. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004, 43:2177-2182.

18. Lilleberg J, Nieminen MS, Akkila J, Heikila L, Luotonen A, Lehtonen L, Verkala K, Mattila S: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998, 19:660-668.

19. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, et al.: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005, 31:638-644.

20. Hona HM, Korge P, Weiss JN: Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci 2005, 1047:248-258.

21. Skuza-Piskinskiene DM, Pollesello P, Saris NE: Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001, 428:311-314.

22. Braun JP, Grosse J, Doepfmer U, von Heymann C: Standards in der Herzchirurgie. In Check-up Anästhesiologie 2nd edition. Edited by: Kox W, Spies C. Heidelberg, Germany: Springer Verlag; 2005:95-133.

23. Calafiore AM, Teodori G, Mezzetti A, Bosco G, Verna AM, Di Giammarco G, Lapenna D.: Intermittent antegrade warm blood cardioplegia. Ann Thorac Surg 1995, 59:398-402.

24. Lehtonen LA, Antila S, Pentikainen PJ: Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 2004, 43:187-203.

25. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peukurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196-202.

26. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, et al.: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002, 23:1422-1432.

27. Lehmann A, Lang J, Boldt J, Isgro F, Keasling AH: Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004, 10:MT99-93.

28. De Backer D, Creteur J, Silva E, Vilcent JL: Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is the best? Crit Care Med 2003, 31:1659-1667.